Kanada - Kiingereza - Health Canada

sivem pharmaceuticals ulc - esomeprazole (esomeprazole magnesium) - tablet (delayed-release) - 20mg - esomeprazole (esomeprazole magnesium) 20mg - proton-pump inhibitors

Kanada - Kiingereza - Health Canada

sivem pharmaceuticals ulc - esomeprazole (esomeprazole magnesium) - tablet (delayed-release) - 40mg - esomeprazole (esomeprazole magnesium) 40mg - proton-pump inhibitors

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - esomeprazole magnesium, quantity: 41.4 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: povidone; macrogol 400; macrogol 6000; microcrystalline cellulose; diethyl phthalate; hypromellose phthalate; crospovidone; macrogol 4000; sodium stearylfumarate; hyprolose; purified talc; titanium dioxide; hypromellose; iron oxide red; maize starch; sucrose - gastro-oesophageal reflux disease (gord),- treatment of erosive reflux oesophagitis,- long-term management of patients with healed oesophagitis to prevent relapse,- symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,- short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazolesolution administered by intravenous infusion,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,- healing of duodenal ulcer associated with helicobacter pylori,- eradication of helicobacter pylori in patients with active or healed peptic ulcer

Kanada - Kiingereza - Health Canada

laboratoire riva inc. - esomeprazole (esomeprazole magnesium dihydrate) - capsule (delayed release) - 20mg - esomeprazole (esomeprazole magnesium dihydrate) 20mg - proton-pump inhibitors

Kanada - Kiingereza - Health Canada

laboratoire riva inc. - esomeprazole (esomeprazole magnesium dihydrate) - capsule (delayed release) - 40mg - esomeprazole (esomeprazole magnesium dihydrate) 40mg - proton-pump inhibitors

Kanada - Kiingereza - Health Canada

pro doc limitee - esomeprazole (esomeprazole magnesium) - tablet (delayed-release) - 20mg - esomeprazole (esomeprazole magnesium) 20mg - proton-pump inhibitors

Kanada - Kiingereza - Health Canada

pro doc limitee - esomeprazole (esomeprazole magnesium) - tablet (delayed-release) - 40mg - esomeprazole (esomeprazole magnesium) 40mg - proton-pump inhibitors

Kanada - Kiingereza - Health Canada

teva canada limited - esomeprazole (esomeprazole magnesium trihydrate) - tablet (delayed-release) - 20mg - esomeprazole (esomeprazole magnesium trihydrate) 20mg - proton-pump inhibitors

Kanada - Kiingereza - Health Canada

teva canada limited - esomeprazole (esomeprazole magnesium trihydrate) - tablet (delayed-release) - 40mg - esomeprazole (esomeprazole magnesium trihydrate) 40mg - proton-pump inhibitors

Marekani - Kiingereza - NLM (National Library of Medicine)

major pharmaceuticals - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole 20 mg - adults esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed ee in adults. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. pediatric patients 12 years to 17 years of age esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of ee in pediatric patients 12 years to 17 years of age.  esomeprazole magnesium delayed-release capsules are indicated for the maintenance of healing of ee in adults. controlled studies do not extend beyond 6 months. adults esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults. pediatric patients 12 years to 17 years of age esomeprazole magnesium delayed-release capsul